BBI Life Sciences Corporation announced that based on the preliminary review of the Group's unaudited consolidated management accounts for the year ended 31 December 2014, the company expects that, without taking into account the non-recurring gain and expense for the year comprising of the recognition of listing expense of approximately RMB 22.5 million; expense of share- based payment of approximately RMB 13.5 million; and gain on disposal of a 31.0% equity interest in Shanghai PrimeGene Bio-Tech Co. Ltd. of approximately RMB 26.4 million to a third-party company in April 2014, the amount of the net profit of the Group for the year may increase by approximately 8% to 12% as compared to that for the corresponding period in 2013, while the amount of the net profit of the group after taking into account the above non-recurring gain and expense may decrease by approximately 12% to 16% as compared to that for the corresponding period in 2013.